Please assess the completion status of the following clinical trial:

Trial Title: Single Dose of pGM169/GL67A in CF Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cystic fibrosis confirmed by sweat testing or genetic analysis~* Males and females aged 16 years and above~* Forced expiratory volume in the 1st second (FEV1) \> 60% predicted values~* Clinical stability at entry~* Prepared to take effective contraceptive precautions for the duration of their participation in the study and for 3 months thereafter~* If taking regular rhDNase (pulmozyme) is willing, and considered able by independent medical carers, to withhold treatment for 24 hours before and 24 hours after the gene therapy dose~* Written informed consent obtained~* Permission to inform GP of participation in study~Exclusion Criteria:~* Infection with Burkholderia cepacia complex organisms or MRSA~* Significant nasal pathology including polyps, clinically-significant rhinosinusitis, or recurrent severe epistaxis (nose bleeds)~* Acute upper respiratory tract infection within the last 2 weeks~* Previous spontaneous pneumothorax without pleurodesis~* Recurrent severe haemoptysis~* Current smoker~* Significant comorbidity including:~  1. Moderate/severe CF liver disease~ 2. Significant renal impairment~ 3. Significant coagulopathy~* Receiving 2nd line immunosuppressant drugs such as methotrexate, cyclosporine, intravenous immunoglobulin preparations~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 20ml pGM169/GL67A (Type: EXPERIMENTAL): Received a nebulized dose 20ml via an breath-actuated nebulizer
- 10ml pGM169/GL67A (Type: EXPERIMENTAL): Received a nebulized dose 10ml via an breath-actuated nebulizer
- 5ml pGM169/GL67A (Type: EXPERIMENTAL): Received a nebulized dose 5ml via an breath-actuated nebulizer

Based on this trial design, predict the completion outcome and termination type (if applicable).